XML 58 R37.htm IDEA: XBRL DOCUMENT
v3.20.4

Commitments and Contingencies - License Agreement (Details) | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
May 31, 2012 USD ($) | Nov. 30, 2008 USD ($) | Dec. 31, 2020 USD ($) item | Dec. 31, 2019 USD ($)
License Agreements |  |  |  |
Accrued license payments |  |  | $ 3,833 | $ 506,000
License Agreement |  |  |  |
License Agreements |  |  |  |
Payments in in satisfaction of deferred annual fees |  |  | 494,000 |
License Agreement | Horizon Therapeutics, PLC |  |  |  |
License Agreements |  |  |  |
One-time non-refundable fee |  | $ 50,000 |  |
Minimum annual commitment |  | $ 40,000 |  |
Amended License Agreement |  |  |  |
License Agreements |  |  |  |
Deferrable minimum annual commitment | $ 46,000 |  |  |
Threshold amount of equity financing | $ 2,000,000 |  |  |
Accrued license payments |  |  | $ 3,833 | $ 506,000
Amended License Agreement | Horizon Therapeutics, PLC |  |  |  |
License Agreements |  |  |  |
Number of milestones achieved | item |  |  | 0 |
Percentage of net sales used to calculate royalties payable |  |  | 5.75% |
Percentage of reduction in royalties payable if third-party license is required |  |  | 50.00% |
Percentage of sublicense income to be paid in addition to royalty payments |  |  | 9.20% |
Period for advance notice of termination |  |  | 90 days |
Term of license agreement |  |  | 10 years |
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option on or after commencement of first Phase II clinical trial |  |  |  |
License Agreements |  |  |  |
Buy-out option price |  |  | $ 500,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option prior to commencement of first Phase II clinical trial and prior to the commencement of the first Phase III clinical trial |  |  |  |
License Agreements |  |  |  |
Buy-out option price |  |  | 1,000,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option prior to commencement of first Phase III clinical trial and prior to the filing of a NDA with the FDA |  |  |  |
License Agreements |  |  |  |
Buy-out option price |  |  | 5,000,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option on or after the filing of a NDA for the first licensed product |  |  |  |
License Agreements |  |  |  |
Buy-out option price |  |  | 8,000,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Commencement of Phase II |  |  |  |
License Agreements |  |  |  |
Amount of milestone payment |  |  | 230,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Commencement of Phase III |  |  |  |
License Agreements |  |  |  |
Amount of milestone payment |  |  | 575,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan) |  |  |  |
License Agreements |  |  |  |
Amount of milestone payment |  |  | 1,150,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Receipt of Regulatory Approval in the United States |  |  |  |
License Agreements |  |  |  |
Amount of milestone payment |  |  | 5,750,000 |
Amended License Agreement | Horizon Therapeutics, PLC | Receipt of Regulatory Approval outside the United States |  |  |  |
License Agreements |  |  |  |
Amount of milestone payment |  |  | $ 5,750,000 |

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments. + References No definition available. + Details
Name: | anvs_AccruedLicensePaymentsCurrent
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The option price at which the license agreement may be bought out by the Company under the terms of the amended license agreement. + References No definition available. + Details
Name: | anvs_BuyOutOptionOptionPrice
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration to be paid by the Company upon the attainment of a milestone as defined in the amended license agreement. + References No definition available. + Details
Name: | anvs_CommitmentsMilestonePayment
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cumulative number of milestones achieved. + References No definition available. + Details
Name: | anvs_CumulativeNumberOfMilestonesAchieved
Namespace Prefix: | anvs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of minimum annual commitment which may be deferred until the Company raises the equity financing level as defined in the amended license agreement. + References No definition available. + Details
Name: | anvs_LicenseAgreementDeferrableMinimumAnnualCommitment
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The minimum amount of annual commitment under the terms of a license agreement. + References No definition available. + Details
Name: | anvs_LicenseAgreementMinimumAnnualCommitment
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The period of advance notice required to terminate the license agreement. + References No definition available. + Details
Name: | anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination
Namespace Prefix: | anvs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The term of the license agreement. + References No definition available. + Details
Name: | anvs_LicenseAgreementTermOfAgreement
Namespace Prefix: | anvs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The threshold amount of equity financing the Company must raise to end deferral of the minimum annual commitment under the terms of the amended license agreement. + References No definition available. + Details
Name: | anvs_LicenseAgreementThresholdAmountOfEquityFinancing
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | anvs_LicenseAgreementsAbstract
Namespace Prefix: | anvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of net sales of licensed products used to calculate royalties payable under the terms of the amended licensing agreement. + References No definition available. + Details
Name: | anvs_LicensedProductsPercentageOfNetSalesUsedToCalculateRoyaltiesPayable
Namespace Prefix: | anvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of reduction in royalties payable if a third-party license is required. + References No definition available. + Details
Name: | anvs_LicensedProductsPercentageOfReductionInRoyaltiesPayableIfThirdPartyLicenseIsRequired
Namespace Prefix: | anvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of sublicense income to be paid in addition to royalty payments under the terms of the amended license agreement. + References No definition available. + Details
Name: | anvs_LicensedProductsPercentageOfSublicenseIncomeToBePaidInAdditionToRoyaltyPayments
Namespace Prefix: | anvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount paid during the reporting period for deferred license commitments. + References No definition available. + Details
Name: | anvs_PaymentsForDeferredLicenseCommitments
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of one-time non-refundable fee paid by the Company at the initiation of a licensing agreement. + References No definition available. + Details
Name: | anvs_PaymentsForLicenseAgreementNonRefundableInitialFee
Namespace Prefix: | anvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anvs_HorizonTherapeuticsPlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=anvs_LicenseAgreementTermsAmendedMay2012Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedOnOrAfterCommencementOfFirstPhaseTwoClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedPriorToCommencementOfFirstPhaseTwoClinicalTrialAndPriorToCommencementOfFirstPhaseThreeClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedPriorToCommencementOfFirstPhaseThreeClinicalTrialAndPriorToFilingOfNewDrugApplicationU.s.FoodAndDrugAdministrationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=anvs_ScenarioBuyOutOptionIfExercisedOnOrAfterFilingOfNewDrugApplicationForFirstLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anvs_CommencementOfPhaseTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anvs_CommencementOfPhaseThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anvs_FilingOfNewDrugApplicationOrEquivalentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anvs_RegulatoryApprovalUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anvs_RegulatoryApprovalOutsideUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |